The Cost Crisis of Weight Loss Drugs

Smart Insurance Choices
22 followers
GLP-1 drugs like Wigovi and ZepBound for weight loss
are all the rage, promising life-changing results.
But at $1,000 or $2,000 a month or more,
who can actually afford them?
For some, insurance foots the bill,
but why for them and not others?
What's driving these coverage decisions
and what does the future hold?
♪♪
Welcome to CareTalk, America's home for incisive debate
about healthcare, business, and policy.
I'm David Williams, president of Health Business Group.
And I'm John Driscoll, the chairman of Waystar.
John, for some people, wrapping up in a blanket
with a mug of hot chocolate
or watching a sporting event with family
is the best way to spend the month of December.
But for others, it's making a list for Santa
or making a snow angel, weather permitting.
So speaking of comfort,
therapy is a great way to bring yourself peace
and that never goes away, even when the season changes.
BetterHelp offers entirely online therapy
that's designed to be convenient, flexible,
and tailored to fit your schedule.
Just fill out a brief questionnaire
to get mashed with a licensed therapist
and switch therapists at any time for no additional charge.
It's helpful for learning positive coping skills
and how to set boundaries.
And it empowers you to be the very best version of yourself.
So whether you're dealing with stress, anxiety,
or seeking personal growth,
BetterHelp connects you with licensed therapists
who can support you on your mental health journey.
Make it a great season with BetterHelp.
Visit betterhelp.com slash caretalk
to get 10% off your first month.
That's betterhelp, H-E-L-P dot com slash caretalk.
Well, John, welcome to December.
Well, Dave, I was with you on the BetterHelp stuff
and it's really an important access point
for getting low cost, wide availability help.
But man, I'm not buying you on the snow angel.
That's just too hard an image for me
to kind of survive that narrative.
But yeah, welcome to our weird December.
Saw that Bill's game in a blizzard.
It sounds like blizzard conditions are coming.
And it's also a season from Thanksgiving
to Christmas and Hanukkah,
where there seems to be a little bit of overeating.
And at a time when obesity and an overweight America
has gone according to the peculiar choice
of Bobby Kennedy from like 10% of the American population
to 60% of the population,
the topic of weight loss drugs is,
if not on people's minds before the holidays,
it's likely to be on it after the holidays,
particularly with the new administration.
So what about all these GLP-1, semi-glutide,
would-go-be, zep-bound, happy, smiling,
overweight people dancing on television?
Like, where are we going here?
Well, they've become extremely popular.
I remember when I first heard about it
and I heard people were paying $1,000 a month or more,
I'm thinking, no one's gonna use that,
but sure enough, they are.
And John, I thought we could talk a little bit
about the state of insurance coverage
for these drugs since they're so important.
I guess you gave me another thought though,
which is maybe if you put it on your list for Santa Claus,
it can pop at least a few into the stocking, but for-
I can't afford that, David.
We don't get paid enough here at CareTalk.
We ought to talk to Vincent about that.
Yeah, I mean, I would say that,
I really hope there is a Santa Claus
so that it could bring me some hope.
But John, it's-
David, before you go there,
do you want to just tell people
a little bit of a background on obesity drugs,
GFP1s and semiglutide?
And you can skip most of the science,
but I think explaining what these drugs are
would contextualize the coverage question.
John, everybody has wanted to have, you know,
a magic pill for weight loss.
And the history of these are riddled with real problems.
Amphetamines, fen-phen, a lot of things that have ended
quite badly.
What's happened here is a little bit different,
which is that some drugs that have been prescribed
for diabetes, which many people have,
had been shown not just to control diabetes,
but actually people had a significant weight loss
as part of it.
And so that gave the drug manufacturers the idea
to actually put these products on the market
for weight loss, which most people want.
So they renamed them, reformulated them a bit,
did some new studies and showed,
hey, these drugs have really significant weight loss
as a starting point.
And then what people are also excited about
is that it may lead to some other improvements
in metabolic conditions like diabetes and heart disease,
and possibly even beyond that.
So we're sort of in the wonder drug phase here,
weight loss, even though people sort of vowed,
hey, we won't go down that road again with a miracle pill.
We won't expect that to work.
Well, I think you make a really important point
about the fact that, again,
contextualizing the need to reduce obesity
or people who are overweight
or particularly morbidly overweight is really important
because one of the most damaging, dangerous
and fastest growing diseases in America is diabetes.
And a lot of obesity predisposes you
because if you lose control of managing your insulin,
it then leads to diabetes, which is a devastating disease
and one that's rapidly growing in,
not just in the United States,
but in every developed country
as people have moved from more traditional diets
to over-eating, to eating the wrong stuff.
That has led to a strong desire to create drugs
that could somehow interfere in that process.
And amphetamines, which were popular,
but quite dangerous and addictive,
to fen-phen, which was just dangerous and effective,
there've been a lot of failed attempts at doing this.
And so the development of the GLP-1s
that, semi-glutide is the active ingredient that's used,
have a couple of impacts that appear to be safe
because there's wide use and very modest,
if any, contrary symptoms.
It reduces the desire to eat.
It reduces cravings, potentially,
around things like alcohol.
And it appears to have an impact on not just the gut
to slow down the processing
so you feel like you're full, but also on the brain.
And we're just, like most drugs,
as they start to scale in phase four,
which is when they are actually in the field
with humans using them,
only now really understanding the full impact
of these drugs.
But they are super popular for the off-label use,
the use that's not prescribed for weight loss.
In fact, the highest concentration of these drugs
appears to be in the Upper East Side of the New York City,
which is the richest part of the country,
when they're really, the primary indication
is for diabetes to kind of reduce that overeating
and that obesity that then could make
the burden of carrying that disease
and kind of managing your life much more easy.
And just to be clear,
these drugs have exploded in popularity across the US,
which is why the question around coverage decisions,
it becomes really important.
And we should get into that
and kind of why coverage
and the idiosyncrasies and inconsistencies there
are really kind of intriguing.
Yeah, it's interesting.
Of course, people were using these products off-label,
as you say, it wasn't their indication for,
they were using them supposed to be for diabetes,
used for weight loss.
Now they have the indication for weight loss
and it's just almost everybody,
most people in the country probably could qualify
in one way or the other.
And it's so difficult to lose weight.
So this becomes a real conundrum for insurance companies,
which they know it probably is good for health long-term,
but their own payoff may not be there
because you're gonna spend a lot of money in the near term,
but it doesn't mean that that health benefit
and that lower cost will come out in the near term.
So there's a real kind of a back and forth.
And some of these things are not just a black and white,
is it covered or it isn't,
but there are some restrictions that would put in place,
things like for prior authorization.
So for example, some plans cover these drugs for weight loss,
but then they say you have to get prior authorization
and it's based on your body mass index.
So just how obese are you,
but also things like your prior weight loss attempts,
like you have to prove that you've tried
and failed something else.
And then also there might be a requirement
for an in-person provider relationship.
So even though you and I are very much in favor
of telehealth, they're also in a way trying
to keep down the use of physicians
or nurse practitioners who are just prescribing this drug
and that's their whole practice,
as opposed to in the context of a broader relationship.
Yeah, I think the context here
is these drugs are growing so fast.
I think that they were $47 billion of revenues
or market in the market in 2024.
By 2032, they're potentially gonna,
if the prices stay at the ridiculously high levels
that they're at, that's gonna be 470 billion.
And so what insurers are worried about
is not just the health of their covered lives,
but first the cost of those covered lives
so they don't go out of business,
and hence all of the restrictions.
The other side of that, Dave,
is that morbid obesity and diabetes
are one of the fastest growing and most dangerous
the cardiometabolic thing is how it's described
leads to heart disease, it leads to cancer,
it leads to very high cost of care, just miserable lives.
And if this wonder drug, this category of drugs
could really stop that, that's pretty amazing.
And so I guess, Dave, if you're running an insurance company
like the brilliant Scrooge-like businessman that you are,
put yourself in that mindset.
How do you start to think about the decisions,
not just what to cover,
but where to cover it for what populations?
Because that starts to get into
the weird idiosyncrasies of coverage.
Well, John, of course, if I just put on my Scrooge hat,
which I didn't bring with me, which I should have,
of course, deny, deny, deny.
It's interesting.
Deny, delay, defer, all the Ds.
It's good to see what's actually happening
and it gives you some evidence.
So one thing that's interesting
is if you look at the employer insurance market
and you look at those companies that are self-insured
versus those that are fully insured, there is a difference.
So the self-insured ones tend to be companies
where there's a longer employee tenure.
So employees tend to be there for a longer time.
There's more of an opportunity to recover the cost,
the finances might actually add up for them.
And so we see that actually self-insured plans
are more likely than the fully insured plans
to offer coverage.
And then they're both more likely
than in the individual market.
The individual market is one where the plans worry about
what they call adverse selection.
And I saw an article that actually compared this
to what happened with HIV drugs.
So the insurers might be required to cover HIV drugs,
but they could put them, make it more or less attractive,
have it in a more expensive formulary tier, et cetera.
They're doing something similar to that.
Do you want to just explain what adverse,
from an insurer, why do you, Ebenezer Scrooge,
why do you care?
What does adverse selection mean and why do you care?
So adverse selection means that you're attracting patients
to your plan that you don't want.
And the main reason you don't want them
is because they're going to be very expensive.
And so you could see why an HIV patient
would be very expensive.
They're sick, they require expensive medication.
So all else being equal, if you're a Scrooge-like insurer,
you don't want them in the plan.
It's a little bit less like that with the weight loss drugs,
but still sort of the same idea.
Hey, people who want weight loss drugs
is going to cost me more to cover the drug,
but also they're probably going to be sicker.
There are supposed to be mechanisms in place, John,
that actually balance this out
so that you're not encouraged to do adverse selection
because you get a higher payment if people are sicker.
But the sense is the risk adjustment
doesn't fully cover this.
And so you see it's quite unusual to have coverage
for these weight loss drugs.
Well, and I think it's actually even harder
when you're dealing with a new drug.
And that was the case of HIV drugs.
Just to contextualize what you're saying
is if I, as Ebeneezer Scrooge,
don't put the most expensive drugs
for people who've got HIV and AIDS in the highest tier,
you, by putting it in the highest tier,
the most expensive drug,
I'm going to draw more HIV patients
to my insurance company versus yours.
And so often early on, while it's unfair
for a lot of the sickest people,
insurance companies will defensively try to tier the cost,
tier meaning increase the cost
for some of these expensive drugs as a defensive mechanism
so they don't feel like they're going to be,
that their costs will not be above average.
Having said that, the way that these drugs
are being handled is kind of weird
because we know that in general,
with millions of people taking them,
they're leading to 15 to 20% weight loss.
We're seeing in clinical trials,
very strong positive reduction of cardiac risk factors.
Heart attack, heart attacks and cancer
are still the most likely way
you're going to get killed in America as an adult.
You die in America that are potentially
preventable and manageable.
And they're pretty, unlike a lot of drugs,
they're apparently pretty easily,
pretty well tolerated by most of the people who take them.
Which is, I think, why it's leading to this disagreement,
which is not uncommon for new drugs
or new procedures that are expensive.
But let's perhaps delve into
some of those inconsistencies in coverage, Dave.
It is peculiar looking at it from the outside.
John, one way, I have to go back,
so you talked about adverse selection.
And my favorite story is actually
one you told me years ago,
and I'm not saying you were involved in this or not,
but back in the early days of Medicare HMOs,
a good way to make sure you got the healthiest patients
was to put the enrollment office
on the fourth floor of a building that had no elevator.
And that was literally,
well before I got into the business
of Medicare managed care,
that's exactly what folks did.
They would require the older enrollees
to see if they could go up the three or four stairways
until that was literally outlawed.
Yeah, yeah.
So anyway, so I like that story.
A good way to look at the different perspectives
on this, John, is to see the decisions that have been made.
I think it was Robert Wood Johnson Foundation
has a coverage, they have a coverage map
where you can look at the different coverages
for the weight loss drugs.
And if you look at Medicaid,
so Medicaid is a program for low-income people
who tend to be sicker.
If you look at where Medicaid benefits are most generous,
they're usually in the more liberal states
like Massachusetts, New York, Connecticut, et cetera.
And that is roughly the case here.
So there's 14 states that cover weight loss drugs
as part of Medicaid.
And it's those blue states I mentioned,
but it's also Mississippi, right?
Which is not a liberal state,
but it's one where that burden of obesity
on the healthcare system is so apparent
that they say, you know what?
This is not a decision about liberal or not.
It's a dollars and cents.
I think we're going to get our payoff soon
if we cover obesity treatment.
Yeah, I think the way to think about this
is whenever there's a new drug or a new procedure,
insurers are all over the place.
I've never seen so many positive results
so quickly around a drug, honestly.
This weight loss has been the uncrackable problem
while it's growing for the entire population.
Diabetes is the most expensive condition for the country.
And anyone who's going to have an employee
for more than a few years
is going to run into this situation
where the long-term costs of avoiding prevention,
the things that you should invest in upfront,
that often, that historically,
a lot of health insurers weren't willing to pay for,
is going to cost you in the long run.
And so what you're seeing is private employers
are starting the self-insured,
those employers that actually pay their own,
effectively self-insured by paying
for their own employees' coverage,
are starting to actually cover this
because they would typically keep an employee
for two or three years or more.
What you're finding in the fully insured
or not insured market is that the insurers
are not covering it as consistently, if at all.
But I think that the underlying,
there's a lot of noise around coverage,
when really the fundamental problem here, Dave,
is these drugs cost too damn much.
Do you want to talk about
how ridiculously expensive these drugs are
and the whole compounding piece
before we then get into the coverage?
Because I think that cost is going to be completely,
is really what's driving some of these conservative
and somewhat idiosyncratic coverage decisions.
Well, John, I knew you were a fanboy for these drugs,
but I didn't know to what exactly extent.
I've never heard-
I'm a fanboy of making them cheaper.
Yeah, okay.
But nonetheless, so yeah.
So in terms of the compounding piece,
so the drugs are expensive,
but they're made from well-known chemicals
that are pretty standard and easy to-
Cheap, cheap, cheap.
Easy to make.
And so there's a huge opportunity,
especially when there's been a shortage of product
on the market, for people to rush in
and fill the void with something that's cheaper
and perhaps equivalent, because it should be.
And so you've got a lot of sites
that are selling these medications
and they're compounding them.
So they're mixing them up themselves.
And they've been allowed to do that
when there's a drug shortage.
That's a bit of a gray area
if the FDA says that shortage isn't there.
And so you see sort of the push and the pull,
but there's a big market of people that are not authorized.
Now, of course, you see the drug companies
going after those folks in any way they can,
suing them, trying to say that it's actually
these drugs are too complicated for compounders
and using our brand name or marketing or whatever.
But yeah, John, they're trying to get paid
based on the value that you're ascribing.
And I mean, just to contextualize this,
these drugs can cost $1,000 or more cash costs,
and yet they're, and obviously the pharma
has its normal ridiculous margins,
but these are very low cost to build and compound.
And there are direct-to-consumer sites
that can make a lot of money
selling them for $100 a month.
So it's literally a 10X difference.
And what the FDA has done,
the companies initially talked about
their own limits and shortages
because the demand is through the roof.
And the demand is through the roof,
not so much because of the insured markets,
but because of the cash market.
And so the FDA responded by allowing the compounders,
compounders, the way I think about compounding
is just smaller batch manufacturing,
more like generic manufacturing.
And those companies are thriving.
As far as I can tell, they don't appear to be
at least reported quality or quality concerns at all.
And so of course, now the big pharma guys
who are the Novos and the Lilies,
I mean, Novo has made so much money
on this particular drug
that it's literally changed the economy of the country.
Yeah, it was not just Legos anymore.
I mean, it's insane.
And the other thing to note
is the way that the pharmacy market is structured.
Most retailers or your local retail pharmacy
is gonna lose money on the distribution,
but the PBMs and the insurers and the farmers
are raking it in.
And so all of those distorted economics
kind of somewhat mask the power of these drugs
to potentially transform the challenge
of obesity in America.
The other thing that's happening then
is that the federal government and state governments
and employers are all trying to figure out
because they don't have the bargaining power
to reduce the cost.
The feds don't only negotiate a few drug prices.
And while pharma is raking it in,
the insurers and the employers
and the people who are making these decisions,
it's getting kind of complicated.
I mean, maybe you could talk a little bit
about what's going on in Medicare and Medicaid
and some of the blues plans.
So for Medicare, John,
the Biden administration has proposed coverage
along also proposed coverage in Medicaid as well.
And they say that could impact about 3 1⁄2 million people
in Medicare and about 4 million in Medicaid
could become newly eligible as a result of this.
And again, just to be clear,
I think they were covered for diabetes before
for the very specific indication,
but this is around obesity and weight loss,
which is a significant problem in the elderly
that leads to lots of other conditions.
Because of the problems with weight loss drugs in the past,
actually Medicare doesn't allow coverage
of weight loss drugs.
It's just as a category.
Now that was before the GLP-1s.
So it could have an impact.
Now, who the heck knows what's gonna go on?
I don't know that Biden is gonna be that influential
in the new administration.
So-
Well, and Bobby, your favorite nominee for HHS,
who I think is a lousy idea, I might add,
is actually really anti-pharma.
Right.
And he sort of suggested, not perhaps unfairly,
that we should fix our food supply and diet problem
before we look at kind of helicopter
spraying drugs all over America.
Yeah, yeah, yeah.
All right.
So let's close up by talking about this topic,
because I could see we could go on all day.
And I'm hungry,
because I'm not taking the required medications.
I'll get you something from HMS.
We can get you a whole pounded thing.
I just saw it on TV.
Get me some weight loss and some testosterone
while we're at it, John.
I could use both.
Well, no, you gotta talk to Bobby about testosterone.
He's the testosterone guy.
So the thing about a couple of notes of caution
here about these drugs.
One is that it hasn't been on the market that long.
It takes a while to see the long-term effects.
So we'll have to see the good effects
and also any bad effects that emerge.
And since it's affecting so many people,
if there's even something that's a small percentage,
it could be a big impact.
The other thing and a reason why some of the blues
have said that they've been withdrawing coverage
is just the question of adherence
and whether people will actually keep taking the medication
for a long enough time to get the benefit.
You get the cost, could come pretty quickly,
spend $10,000 or so,
but maybe you don't get the longer term benefit
and that's something to worry about.
Now on this question about the food supply.
So this, I would say,
has been mirrored a little bit with statins.
So as you may remember,
there was a lot of discussion before
about people getting their cholesterol down
and diet and exercise and this sort of thing.
And it was damn hard to get anybody to do that.
Really hard.
It's just about as hard as weight loss.
Yeah, impossible.
So they said statin is kind of, that's the message.
Now, Bobby may have the right idea potentially
about big food, but you know what?
He's not running the Department of Agriculture
and the Department of Agriculture is gonna be run.
Big food.
Yeah.
Process, process, process.
I don't think there's gonna be anything really that's done
other than the talk in this new administration
on the food question.
It's gonna give us plenty to talk about, David.
Yeah.
All right, food for thought, John.
And we'll go over for dessert.
So anyway, that's it for yet another episode of Cure Talk.
We've been talking about GLP-1 drugs,
weight loss, how they're paid for,
and various miscellaneous topics as well.
I'm David Williams, President of Health Business Group.
And I'm John Driscoll, Chairman of Waystar.
If you like what you heard, what you did,
we'd love you to subscribe on your favorite service.
